课题基金 / 基金详情

ANTI TNF ANTIBODY D2E7 IV INJECTION IN RHEUMATOID ARTHRITIS

ANTI TNF ANTIBODY D2E7 IV INJECTION IN RHEUMATOID ARTHRITIS
抗TNF抗体D2E7静脉注射治疗类风湿性关节炎
批准号：
6265190
负责人：
MICHAEL H WEISMAN
金额：
$1.15万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN DIEGO
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6265190
关键词：
antibody clinical research clinical trial phase I combination chemotherapy dosage drug screening /evaluation drug tolerance human subject human therapy evaluation immunogenetics intravenous administration methotrexate rheumatoid arthritis sign /symptom skeletal disorder chemotherapy synovitis tumor necrosis factor alpha

项目摘要

项目成果

MICHAEL H WEISMAN的其他基金

相似基金

相关文献

中文摘要
翻译
研究类风湿关节炎患者联合甲氨蝶呤治疗后反复递增剂量D2E7的临床药理学特征、安全性、耐受性、免疫原性和临床疗效的早期迹象。通过标准临床和实验室参数评估D2E7和甲氨蝶呤联合治疗炎性滑膜炎的发病、程度和持续时间。
英文摘要
Investigate the clinical pharmacology profile, safety, tolerability, immunogenicity and early signs of clinical efficacy following repeated administration of ascending doses of D2E7 in patients with rheumatoid arthritis treated concomitantly with methotrexate. Evaluate onset, magnitude and duration of effects of a combination of D2E7 and methotrexate on inflammatory synovitis, assessed by standard clinical and laboratory parameters.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
INDUCTION COURSE & MAINTENANCE CYCLE OF AG4263 IN RHEUMATOID ARTHRITIS
LJP 394 ADMINISTERED TO PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
RECOMBINANT HUMAN INTERLEUKIN ELEVEN IN RHEUMATOID ARTHRITIS
STUDY OF ORAL CCII IN TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS
海外基金